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Abstract Cardiovascular disease remains the lead-
ing cause of mortality, morbidity and disability in the
developed world, predominantly affecting the adult
population. In the early 1990s coronary heart disease
(CHD) was established as affecting one in two men
and one in three women by the age of forty. Despite
the dramatic progress in the field of cardiovascular
medicine in terms of diagnosis and treatment of heart
disease, modest improvements have only been
achieved when the reduction of cardiovascular mor-
tality and morbidity indices are assessed. To better
understand coronary atherosclerosis, new imaging
modalities have been introduced. These novel imag-
ing modalities have been used in two ways: (1) for
the characterization of plaque types; (2) for the
assessment of the progression and regression of tissue
types. These two aspects will be discussed in this
review.
Keywords Intravascular ultrasound 
Tissue characterization  Atherosclerosis
Introduction
Atherogenesis is a chronic and evolving inflamma-
tory process. Many theories have been proposed to
explain the initiation and progression of the athero-
matous plaque from the asymptomatic ‘‘raised fatty
streak or intimal xanthoma’’ and proatheroma (types
II and III lesions respectively_AHA classification) to
the formation of the symptomatic and obstructive
complicated fibroatheroma (type VI lesion_AHA
classification). During the formation of these plaques,
a critical primary step is the accumulation and
oxidation of low-density lipoprotein (LDL) particles.
Oxidized-LDL favours leukocyte recruitment and
activation as well as cell death, which leads to the
generation of complex atherosclerotic plaques [2].
These high-risk atherosclerotic plaques have a par-
ticular phenotype that is characterized by a high
content of necrotic core, a thin inflamed fibrous cap
(due to intense accumulation of macrophages) and
the scarce presence of smooth muscle cells. Within
the necrotic core, underlying the thin fibrous cap,
hemorrhage, calcification and intraplaque vasa vaso-
rum are frequently found [3, 4].
IVUS and IVUS-based imaging modalities have
the potential to be able to provide useful insights
into the different phases of the development of the
plaque, as well as the different key players in this
process (i.e. components of the plaque such as
necrotic core). In this review, we will discuss the
capabilities and limitations of IVUS-based tissue
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characterization imaging modalities in providing this
information.
Plaque type characterization
Detection of calcification
On IVUS, calcium appears as bright echoes with
acoustic shadowing. Dense calcium obstructs the
penetration of ultrasound Fig. 1. As a consequence,
IVUS detects only the leading edge of calcium and
therefore cannot determine its thickness. Calcification
on IVUS is usually described by its circumferential
angle (arc), longitudinal length and depth. Calcifica-
tion can be located deeper in the arterial wall or at the
surface of the plaque, in close contact with the lumen
wall interface, and can produce reverberations or
repeated reflections at reproducible distances. IVUS
has shown a significantly higher sensitivity than
fluoroscopy in the detection of coronary calcification.
[5] As compared to histology, virtual histology has a
predictive accuracy of 96.7% in the detection of
dense calcium [6] (Fig. 1).
Arterial remodeling and plaque composition
Arterial remodeling refers to a continuous process
involving changes in vessel size as measured by the
EEM cross-sectional area; this is also known as the
vessel cross-sectional area—CSA. ‘‘Positive remod-
eling’’ occurs when there is an outward increase in
EEM and ‘‘negative remodeling’’ occurs when the
EEM decreases in size (i.e. shrinkage of the vessel)
[7]. The magnitude and direction of remodeling can
be expressed by following index: EEM cross-sectional
area at the plaque site divided by EEM CSA at the
reference ‘‘non-diseased’’ vessel site. Positive remod-
eling demonstrates an index [1.05 whilst negative
remodelling has an index \0.95. Direct evidence of
remodeling can only be demonstrated in serial studies
showing changes in the EEM CSA over time, since
remodeling may also occur at the ‘‘normal-appearing’’
reference coronary segment [7]. The limitations of
coronary angiography in determining disease burden
and stenosis severity are largely due to the effects of
vessel remodeling. Pathological studies have also
suggested a potential relationship between positive
vessel remodeling and plaque vulnerability. Vessels
Fig. 1 Cross sections of IVUS and corresponding VH-IVUS
frames characterizing a calcified plaque. Grey scale IVUS has
both a high sensitivity and specificity in the detection of
calcium. Calcium usually obstructs the penetration of
ultrasound and consequently obscures the imaging of the
underlying vascular wall; this phenomenon is known as
acoustic shadowing (thin white arrows in the top panel). The
corresponding IVUS virtual histology frames are shown at the
bottom of the figure with the dense calcium being shown in
white. The greyscale image is reconstructed from the
amplitude of the signal whereas with virtual histology, the
underlying radiofrequency data is used for tissue character-
ization as illustrated
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with positive remodeling have shown an increase in
inflammatory marker concentrations, larger lipid
cores, paucity of smooth muscle cells and medial
thinning [8–10]. Several IVUS studies have linked
positive vessel remodelling with culprit [11] and
ruptured coronary plaques [12, 13]. Positive remod-
elling has also been observed more often in patients
with acute coronary syndromes than in those with
stable coronary artery disease [14, 15], and has been
identified as an independent predictor of major
adverse cardiac events in patients with unstable
angina [16]. Plaques exhibiting positive remodelling
also more often have evidence of thrombus and signs
of rupture [17]. The patterns of remodelling have also
been correlated with plaque composition; soft plaques
are associated with positive remodelling whilst fibro-
calcific plaques are more often associated with
negative or constrictive remodelling [18]. Similar
findings have been observed in studies utilizing IVUS
virtual histology analyses, a technique developed
specifically for tissue characterization; positive
remodelling was found to directly correlate with the
presence and size of necrotic core, and was inversely
associated with the presence of fibrotic tissue [19].
Vulnerable plaque and thrombi
Acute coronary syndromes are often the first mani-
festation of coronary atherosclerosis, making the
identification of plaques at high-risk of complications
an important component of strategies to reduce
casualties associated with atherosclerosis. Our current
understanding of plaque biology suggests that *60%
of clinically evident plaque rupture originates within
an inflamed thin-capped fibroatheroma [20, 21].
Pathological studies have demonstrated that ruptured
plaques are mainly located in the proximal portions
of the LAD and LCX and are more disperse within
the RCA [22]. This tendency of advanced plaques to
preferentially develop in these locations has been
explained by the low shear stress conditions gener-
ated in areas with tortuosity or many branches. Low
shear stress may induce the migration of lipid and
monocytes into the vessel wall, which may lead to
further progression of the lesion towards a plaque
with high risk of rupture [23].
The definition of an IVUS-derived TCFA is a
lesion fulfilling the following criteria in at least 3
frames: (1) plaque burden C40%; (2) confluent
necrotic core C10% in direct contact with the lumen
(i.e. no visible overlying tissue) [24]. By using this
definition of IVUS-derived TCFA, in patients with
ACS who underwent IVUS of all three epicardial
coronaries, on average 2 IVUS-derived thin cap
fibroatheromas were found per patient with half of
these patients showing evidence of outward remod-
elling. [24].
Hong et al. [25] reported the frequency and
distribution of TCFA identified by virtual histology
intravascular ultrasound in acute coronary syndrome
(ACS = 105 pts) and stable angina pectoris
(SAP = 107 pts) in a 3-vessel IVUS-VH study. The
findings showed that there were 2.5 ± 1.5 TCFAs per
patient with ACS and 1.7 ± 1.1 TCFAs per patient
with SAP, P \ 0.001. The presentation of ACS was
the only independent predictor for multiple ID-TCFA
(P = 0.011). 83% of ID-TCFAs were located within
40 mm of the proximal coronary artery.
The potential value of these VH IVUS-derived
plaque types to predict adverse coronary events was
evaluated in an international multicentre prospective
study, the Providing Regional Observations to Study
Predictors of Events in the Coronary Tree study
(PROSPECT study) [26].
The PROSPECT trial was a multi-center, natural
history study of acute coronary syndrome patients.
All patients underwent PCI to their culprit lesion at
baseline, followed by an angiogram and IVUS virtual
histology of all three major coronary arteries. One of
the main findings was that a TCFA, with a minimum
lumen area of B4 mm2, and a large plaque burden
(C70%), had a 17.2% likelihood of causing a future
event within three years [26]. Interestingly, the
anticipated higher frequency of acute thrombotic
cardiovascular events did not occur, with only a 1%
rate of myocardial infarction and no deaths directly
attributable to non-culprit vessels over a period of
3 years follow-up. These results suggest that non-
culprit obstructive coronary plaques were more likely
to be associated with increasing anginal symptoms
rather than thrombotic acute events, with 8.5% of
patients presenting with worsening angina and 3.3%
with unstable angina.
Plaque ruptures occur at sites of significant plaque
accumulation, but are often not highly stenotic, as
defined by coronary angiography due to positive
vascular remodeling [12, 13, 27]. The transition to
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plaque rupture has been characterized by the presence
of active inflammation (monocyte and macrophage
infiltration), thinning of the fibrous cap (\65 lm),
development of a large lipid necrotic core, endothe-
lial denudation with superficial platelet aggregation
and intraplaque hemorrhage [28]. The remaining
plaques that can cause ACS contain calcium nodules
(*10%) or have none of the pathological features
described above (*20%). Superficial plaque erosion
can explain at least a portion of the latter events,
particularly in women and diabetics [29]. The lack of
a cellular or anatomical signature of plaque erosion
can make it difficult for existing imaging methods to
have a high accuracy in predicting future ACS events.
In addition, most plaque ruptures are frequently
clinically silent; the occurrence of repetitive healed
plaque ruptures may contribute to the progression of
stable coronary disease into obstructive disease [30].
Ruptured plaques may have a variable appearance
on IVUS. Most commonly, IVUS may reveal an
‘‘axial’’, abrupt ulceration depicted as an echolucent
‘‘void’’ or cavity beginning at the luminal-intimal
border. These features should be distinguished from a
longitudinal tear of the intima and media associated
with spontaneous or iatrogenic dissection. The tear of
the rupture in the fibrous cap can be identified in
approximately 60% of the cases and occurs more
often at the shoulder of the plaque than in the centre
[12, 31, 32]. Due to its relatively poor resolution,
IVUS is unsuitable to detect a thin fibrous cap.
However, IVUS often reveals other features of
ruptured plaques which are large in volume, eccen-
tric, have mixed or soft composition and irregular
surface, and are associated with expansive remodel-
ling [12, 13, 33, 34]. Ruptured plaques have been
shown to have quantitatively less calcium, especially
superficial calcium, but a larger number of small
(\908 arc) calcium deposits, particularly deep cal-
cium deposits [35]. IVUS can also reveal blood
speckles passing through intra-plaque channels cre-
ated by the rupture. These usually produce a typical
hazy, complex with non stenotic angiographic
appearances of the ruptured plaques.
Several IVUS studies have reported the frequency
and distribution of plaque ruptures during investiga-
tion of the three coronary epicardial vessels. Rioufol
et al. studied 24 patients (72 arteries) with ACS and
found a mean prevalence of two ruptured plaques per
patient. Interestingly, 12.5% of these patients had
ruptured plaques in the three major coronary arteries.
Only 37.5% of the ruptured plaques were located at
the culprit lesion, and 79% of the patients also had a
ruptured plaque located somewhere other than at the
culprit lesion [36]. In a similar study in 45 patients
with acute myocardial infarction (AMI), plaque
rupture was observed in 21 patients (47%) at the
culprit site and 17 additional plaque ruptures were
found at remote sites in 11 patients (24%) [37]. Hong
et al., evaluated the incidence of plaque rupture
depending on the clinical presentation. They per-
formed 3-vessel IVUS examination in 235 patients
(122 AMI and 113 stable angina pectoris—SAP).
Plaque rupture of infarct-related or target lesions
occurred in 66% of AMI patients and in 27% of SAP
patients. Non-infarct-related or non-target artery
plaque ruptures occurred in 17% of AMI patients
and 5% of SAP patients. Multiple plaque ruptures
were observed in 20% of AMI and 6% of SAP
patients [38]. The same authors evaluated the distri-
bution of plaque rupture in native coronary arteries in
392 patients (231 ACS and 161 SAP). Three-vessel
IVUS imaging showed that plaque ruptures occurred
mainly in the proximal segments of the LAD (83% of
LAD ruptured plaques), the proximal and distal
segments of the RCA (48 and 32% of RCA ruptured
plaques, respectively), and the entire LCX [39].
These results are in line with another study that
included 104 patients and studied 160 ruptured
plaques in the LAD, the majority of plaque ruptures
were located within the proximal 30 mm of the artery
[40].
A study aimed at characterizing plaque ruptures in
the left main coronary artery (LMCA) found 16
plaque ruptures in 17 patients (2 AMI, 13 unstable
angina and 1 SAP). The ruptures were located in the
distal portion and/or bifurcation of the LMCA, often
did not compromise the lumen, and had an angio-
graphic complex appearance. When ruptured plaques
involved the bifurcation LAD-LCX, they often
occurred opposite to the flow divider [41]. This is
in line with findings made by our group; lesions
involving the bifurcation LAD-LCX were predomi-
nantly located in the outer wall of the carina, and
such locations were often associated with a larger
necrotic core content [42].
Ruptured atherosclerotic plaques in native coro-
nary arteries are well described with intravascular
ultrasound; they are however, not well described in
228 Int J Cardiovasc Imaging (2011) 27:225–237
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saphenous vein grafts (SVGs). In 791 pre-interven-
tion IVUS SVG studies, 95 ruptured plaques in 76
SVGs (73 patients) were identified (prevalence of
9.7%). These ruptured plaques were found to be
associated with complex angiographic characteristics
and expansive remodelling [43, 44]. Likewise, in an
analysis of 300 ruptured plaques in SVGs in 254
patients, Maehara et al., demonstrated that ruptured
plaques, as detected by IVUS, strongly correlated
with a complex angiographic lesion morphology:
ulceration in 81%, intimal flap in 40%, thrombus in
7%, and aneurysm in 7% [12].
IVUS has also been used to assess the natural
evolution of ruptured plaques. IVUS studies have
suggested that up to 50% of the ruptured plaques
detected in a first ACS event heals with medical
therapy, without a significant change in plaque size
[45]. One study revealed complete healing of plaque
rupture in 29% of patients treated with statins and
incomplete healing in untreated patients [46].
The ruptured plaque profile in 40 patients referred
for cardiac catheterization has previously been
described [47]. In total, there were 13 patients with
stable angina, 12 with unstable angina, and 15 with
acute myocardial infarction. Ruptured plaque was
identified in 26 patients and, as expected, was more
frequent in patients with acute myocardial infarction
and unstable angina. Patients with ruptured plaques
were found to have a larger body mass index, were
more likely to be smokers and had more diffuse
calcification and necrotic core areas when compared
to those patients without plaque rupture. Of note, is
that the location of plaque ruptures in this study
mirrored the pathological findings [48]. In a study
performed by our group, the proximal left anterior
descending coronary artery was the most common
site of plaque rupture. In a pathological series of 79
ruptures, Burke et al. [48] found 74% of the plaque
ruptures occurred in the proximal left anterior
descending artery.
Similarly, in a report by Hong et al., the frequency
and distribution of ruptured plaques identified by
IVUS-VH in acute coronary syndrome (ACS = 105
pts) and stable angina pectoris (SAP = 107 pts) in a
3-vessel IVUS-VH study were reported. [25] 76
ruptured plaques (55 in ACS and 21 in SAP) were
described with the presentation of ACS being the
only independent predictor for multiple plaque rup-
tures (P = 0.013).
Although plaque characteristics do not yet influ-
ence current therapeutic guidelines, the available
clinical imaging modalities, IVUS and IVUS-based
tissue characterization techniques such as virtual
histology, integrated basckscattered IVUS and iMap,
have the ability to identify some of the pathological
atheroma features described above (Fig. 2).
Thrombus represents the ultimate pathological fea-
ture leading to ACS. Thrombus is usually recognized as
FT
PIT
FC
CaTCFACa FA TCFAFA
IMT
Fig. 2 Examples of VH-IVUS images classified by a two-
dimensional lesion analysis. (IMT) intimal medial thickening;
(PIT) pathological intimal thickening; (FT) fibrotic plaque;
(FC) fibrocalcific plaque; (FA) fibroatheroma and (caFA)
calcified fibroatheroma; (VH-TCFA) Virtual Histology-thin
cap fibroatheroma and (VH-caTCFA) Virtual Histology-
calcified thin cap fibroatheroma. Reprinted from EuroInter-
vention Vol 5, number 2, Garcia-GArcia HM et al. Tissue
characterisation using intravascular radiofrequency data anal-
ysis: recommendations for acquisition, analysis, interpretation
and reporting. Pages 186. Copyright (2009), with permission
from Europa Edition
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an echolucent intraluminal mass, often with a layered or
pedunculated appearance by IVUS [7]. Fresh or acute
thrombus may appear as an echodense intraluminal
tissue, which does not follow the circular appearance of
the vessel wall, whilst older, more organized thrombus
has a darker ultrasound appearance. However, none of
these IVUS features are a hallmark for thrombus, and
one should consider slow flow (fresh thrombus), air,
stagnant contrast or black hole, an echolucent neoin-
timal tissue observed after DES and radiation therapy,
as differential diagnoses [7].
None of the IVUS-based imaging modalities
available can reliably identify thrombus.
Assessment of progression/regression of coronary
atherosclerosis
Quantification of atheroma or plaque area in cross-
sectional IVUS images is performed by subtracting
the lumen area from the EEL area. Hence, IVUS
defined atheroma area is a combination of plaque plus
media area. The atheroma area can be calculated in
each frame (cross-sectional image), and total ather-
oma volume (TAV) can be calculated based on
pullback speed during imaging acquisition. Atheroma
volume can be reported as the percent of the volume
of the external elastic membrane occupied by ather-
oma namely percent atheroma volume (PAV).
Parameters commonly used to report the extent of
the coronary atherosclerosis are shown in (Fig. 3).
Measurements are performed between the inner
lumen border and the media, delineated by the IEL,
which corresponds to the ‘‘true’’ histological area of
the atheroma. Intravascular imaging has played an
important role in the understanding of atherosclerosis
disease in humans and translation of novel therapies
to the clinical arena.
Drug effects on atherosclerosis
The initial observations about a expansive continuous
relationship between coronary heart disease risk and
blood cholesterol levels led to the conduction of a
number of IVUS-based studies to evaluate the effec-
tiveness of differing lipid lowering drugs on atheroma
size. Changes in plaque characteristics may be a more
relevant endpoint to predict the risk of vascular
thrombosis than plaque progression or regression of
mild to moderate disease. Imaging tools to accurately
evaluate plaque characteristics were not available
until recently. Other limitations of using conventional
grayscale IVUS to assess the natural history of
atherosclerosis should be enumerated: (1) Catheteri-
zation, which is an invasive procedure, is required for
serial imaging; (2) only a segment of the coronary tree
can be studied; (3) plaque composition is not
obtained; (4) there is no direct evidence linking
changes in coronary plaques and clinical events.
The efficacy of lowering LDL-C with inhibitors
of hydroxymethylglutaryl coenzyme A reductase
(statins) is unequivocal; however the change in
atheroma size by statins is not constant across all
IVUS studies. There are many potential explanations
for these discrepancies in IVUS studies, such as
drug properties, dose, and duration of treatment.
Other medications have been studied with IVUS
greyscale and IVUS derived imaging modalities
(Table 1).
Nevertheless, no single report has been described
showing a clear and direct association between
reduction in plaque size, composition and/or plaque
type with the reduction in clinical events. This is in
part due to the fact that clinical outcome studies are
expensive, since they have to include a large
population (that should be imaged in at least at 2
different time points) that have to be followed up for
a prolonged period of time in order to ensure the
required number of events have occurred (which are
becoming scarce due to the improvements in stan-
dards of care) in order to best assess the treatment
effect.
Volumetric quantification of the extent of atherosclerosis in coronary arteries
TAV = Σ (EEMCSA−LUMENCSA)
EEMCSA−LUMENCSA
number of analyzed frames per patient
TAVnorm = Σ
X
mean/median no. 
of analyzed frames 
in the population
TAV (follow-up) − (baseline)
TAV (baseline)% change in TAV =
X 100
Σ (EEMCSA−LUMENCSA)
Σ EEMCSA
PAV = X 100
Fig. 3 Parameters commonly used to report the extent of the
coronary atherosclerosis are total atheroma volume (TAV) and
percent atheroma volume (PAV). EEM, external elastic
membrane; CSA, cross-sectional area
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